본문 바로가기

PAPER

 (7)
Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A Abstract Introduction Current Methods in the Coagulation Laboratory FVIII and Emicizumab: Similarities and Differences Impact and Interference of Emicizumab on Current Laboratory Assays Assay Alternatives Conclusion References Abstract 이중특이성 단클론 항체인 에미시주맙은 효과적인 지혈을 회복하기 위해 FIXa와 FX를 연결함으로써 FVIIIa의 기능을 모방합니다. 에미시주맙과 FVIII는 일부 기능적 유사성을 보이지만 에미시주맙이 있는 상태에서 수행할 때 표준 실험실 분석 결과에 몇 가지 주요 차이점이 영향을 미칩니다...
[ARTICLE] 2012 Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight Sven Björkman, MyungShin Oh, Gerald Spotts, Phillip Schroth, Sandor Fritsch, Bruce M. Ewenstein, Kathleen Casey, Kathelijn Fischer, Victor S. Blanchette and Peter W. CollinsBlood 2012 119:612-618; doi: https://doi.org/10.1182/blood-2011-07-360594AbstractComparison of the pharmacok..
[ARTICLE] 2016 A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATEAuthorsP. L. Turecek,S. Romeder-Finger,C. Apostol,A. Bauer,A. Crocker-Buqué,D. A. Burger,R. Schall,H. GritschFirst published: 28 June 2016Full publication historyDOI: 10.1111/hae.13001 View/save citationCited by (CrossRef): 1 art..
[ARTICLE] 2017 Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B Explore this journal >Previous article in issue: Platelet Rich Plasma for Chronic Synovitis Treatment in Patients with HaemophiliaNext article in issue: Instructions for AuthorsView issue TOC Volume 23, Issue 4 July 2017 Pages 620–627Original ArticleDiscrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia BAuthorsK. Kihlberg,K. Strandberg,S. Rosén,R. Ljung,J. A..
[ARTICLE] 2017 Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path? Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path?Emmanuel J. Favaloro1 and Giuseppe Lippi2Author information ► Article notes ► Copyright and License information ►Hemophilia defines a condition that predisposes to bleeding, and is caused by deficiency or defect in certain clotting factors, the most common being Hemophilia A ..
[ARTICLE] 2009 Factor VIII Inhibitor Assays: Methodology, Shortcomings, and Challenges Factor VIII Inhibitor Assays: Methodology, Shortcomings,and Challenges M van Geffen1, M Dardikh1 and B VerbruggenAffiliation: Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands A B S T R A C TDevelopment of inhibitory antibodies against factor VIII is a serious complication in the treatment of hemophilia patients, as..
[ARTICLE] 2015 One-stage vs. chromogenic assays in haemophilia A Eur J Haematol. 2015 Feb;94 Suppl 77:38-44. doi: 10.1111/ejh.12500. Eur J Haematol. 2015 Feb;94 Suppl 77:38-44. doi: 10.1111/ejh.12500.One-stage vs. chromogenic assays in haemophilia A.Potgieter JJ1, Damgaard M, Hillarp A. AbstractHaemophilia A severity is closely correlated to the factor VIII (FVIII) activity, which can be measured in different ways. The original one-stage clotting assay is still the most widely used. The two-stage coagulation assay eliminated ..

티스토리툴바